Please login to the form below

Not currently logged in
Email:
Password:

Questcor appoints SVP corporate strategic development

Michael Aldridge joins from Australian early development company Xenome

US biopharma Questcor Pharmaceuticals has named Michael Aldridge as its first senior VP, corporate strategic development.

His main responsibilities will include identifying potential partnerships and acquisitions for the company, which specialises in developing treatments for difficult-to-treat autoimmune and inflammatory disorders.

These moves could see it expand outside the US with its lead product HP Acthar Gel  (repository corticotropin injection), an injectable drug, which is approved by the FDA in several indications including the treatment of proteinuria in idiopathic types of nephrotic syndrome and the treatment of acute exacerbations of multiple sclerosis in adults.

Development programmes that complement Acthar are also a potential as Questcor looks to expand.

"Michael brings an extensive background in the global biotechnology and pharmaceutical industries that is relevant to Questcor's long term strategic growth and development," said Steve Cartt, chief operating officer of Questcor.

"Our flagship product, Acthar, has proven to be a product of great clinical utility and promise, and the addition of Michael to the Questcor team bolsters our ability to further build our portfolio within a longer term global strategy.”

Aldrige's most recent position was as CEO and managing director of Xenome, an Australia-headquartered early development company.

He has also served as CEO and managing director of Peplin, a company that was acquired by LEO Pharma.

Prior to joining the healthcare industry, Aldridge was an investment banker holding senior positions at firms including Wilson HTM Investment Group, Bear Stearns & Co and Volpe.

30th January 2013

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics